知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

214 条记录 (耗时 0.035 秒)

    ANTIBODIES AND METHODS FOR THE DETECTION OF CELL DEATH
    1.
    发明公开
    ANTIBODIES AND METHODS FOR THE DETECTION OF CELL DEATH 审中-公开

    公开(公告)号：US20240310386A1

    公开(公告)日：2024-09-19

    申请号：US18532159

    申请日：2023-12-07

    申请人： PHARMA CINQ, LLC

    发明人： Jeffrey Allan MILLER ,  Eddie Phillip JEFFRIES

    IPC分类号： G01N33/68 ,  C07K16/18 ,  G01N33/543

    CPC分类号： G01N33/6893 ,  C07K16/18 ,  G01N33/54333 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/72 ,  G01N2333/4742 ,  G01N2510/00 ,  G01N2800/085 ,  G01N2800/7033

    摘要： Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK18 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unbound or excess material; and detecting the signal from the detection moiety, wherein the signal is positively correlated with the presence of the CK18 protein fragment in the sample.

    PROGNOSTIC VALUE OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING STABLE DISEASE
    4.
    发明公开
    PROGNOSTIC VALUE OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING STABLE DISEASE 审中-公开

    公开(公告)号：US20230358750A1

    公开(公告)日：2023-11-09

    申请号：US18352183

    申请日：2023-07-13

    申请人： Roche Diagnostics Operations, Inc.

    发明人： Anika Mang ,  Thomas Muley ,  Vinzent Rolny ,  Birgit Wehnl

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57423 ,  G01N2333/4742 ,  G01N2333/4725 ,  G01N2333/70596

    摘要： The present invention relates to an in vitro method for assessing the risk of non-small cell lung carcinoma (NSCLC) disease progression for a subject classified to have stable disease under an ongoing NSCLC treatment regime. The method involves determining the level of CYFRA 21-1 and/or the level of CA 125 in a sample obtained from the subject; and comparing (i) the determined level of CYFRA 21-1 to a CYFRA 21-1 cut-off level, (ii) the determined level of CA 125 to a CA 125 cut-off level, or (iii) a score taking into account the determined level of CYFRA 21-1 and/or the determined level of CA 125 to a cut-off score. The method of the invention further allows for assessing whether the subject responds to the ongoing treatment and/or whether the treatment regime should be maintained or modified. The invention also provides for corresponding uses, computer-implemented methods and computer program products.

    METHODS FOR DETERMINING PROGNOSIS OF COLORECTAL CANCER
    7.
    发明申请
    METHODS FOR DETERMINING PROGNOSIS OF COLORECTAL CANCER 审中-公开

    公开(公告)号：US20180196052A1

    公开(公告)日：2018-07-12

    申请号：US15876732

    申请日：2018-01-22

    申请人： MORPHOTEK, INC.

    发明人： Daniel John O'SHANNESSY ,  Nicholas C. NICOLAIDES ,  Elizabeth B. SOMERS

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57419 ,  G01N2333/4742 ,  G01N2333/71 ,  G01N2333/78

    摘要： Provided herein are methods for determining the risk that a subject diagnosed with colorectal cancer will develop a recurrence of colorectal cancer and methods of predicting clinical outcome for a subject diagnosed with colorectal cancer by a) determining the level of expression for each marker of a panel of markers in a panel of tumor compartments in a tumor tissue sample from the subject, wherein the panel of markers comprises at least two of TEM1, HIF2α, CAIX, PDGFRβ, fibronectin, collagen I, collagen IV, and CD31 and wherein the panel of tumor compartments comprises at least three tumor compartments of pure stroma, tumor, stromal vessel, and tumor vessel; b) determining the TAPPS score for said subject; and c) comparing the TAPPS score of the subject to the TAPPS score of a population of subjects diagnosed with colorectal cancer. Also provided are related computer-implemented methods and systems, kits, and tumor microarrays.

    METHODS FOR THE DETECTION AND QUANTIFICATION OF CIRCULATING TUMOR CELL MIMICS
    9.
    发明申请
    METHODS FOR THE DETECTION AND QUANTIFICATION OF CIRCULATING TUMOR CELL MIMICS 审中-公开
    循环肿瘤细胞检测和定量方法

    公开(公告)号：US20160341732A1

    公开(公告)日：2016-11-24

    申请号：US15115225

    申请日：2015-01-29

    申请人： EPIC SCIENCES, INC.

    发明人： Ryan Dittamore

    IPC分类号： G01N33/574 ,  G01N33/569

    CPC分类号： G01N33/57488 ,  G01N33/56966 ,  G01N33/56972 ,  G01N33/57423 ,  G01N2333/4742 ,  G01N2333/70589 ,  G01N2333/70596 ,  G01N2333/755 ,  G01N2333/916 ,  G01N2500/10

    摘要： The disclosure provides methods for detecting circulating endothelial cells (CECs) that mimic CTCs with respect to aspects of their immunofluorescent staining and with respect to aspects of their morphological characteristics (CTC mimics). The present disclosure is based, in part, on the unexpected discovery that CTC mimics can be detected in non-enriched blood samples among CTC candidate cells. The present disclosure is further based, in part, on the discovery that CTC mimics can be detected in non-enriched blood samples by combining the detection of one or more immunofluorescent markers in the nucleated cells of a non-enriched blood sample with an assessment of the morphology of the nucleated cells.

    摘要翻译： 本公开提供了检测循环内皮细胞（CEC）的方法，所述循环内皮细胞（CEC）相对于其免疫荧光染色的方面以及关于它们的形态特征（CTC模拟物）的方面模拟CTC。 本公开部分地基于意外发现可以在CTC候选细胞中的非富集血液样品中检测CTC模拟物。 本公开进一步基于以下发现：通过将非富集血液样品的有核细胞中的一种或多种免疫荧光标记物的检测与未富集的血液样品的检测结合，可以在非富血液样品中检测CTC模拟物 有核细胞的形态。